A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

Bortezomib therapy has proven successful for the treatment of relapsed, relapsed/refractory, and newly diagnosed multiple myeloma (MM). At present, bortezomib is available as an intravenous injection, and its prolonged treatment is associated with toxicity and development of drug resistance. Here we...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Chauhan, Dharminder, Singh, Ajita V., Aujay, Monette, Kirk, Christopher J., Bandi, Madhavi, Ciccarelli, Bryan, Raje, Noopur, Richardson, Paul, Anderson, Kenneth C.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2010
Teme:
Lymphoid Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3321748/
https://ncbi.nlm.nih.gov/pubmed/20805366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-04-276626
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki